PumasAI helps launch India’s first computational lab for quantitative sciences

PumasAI said it helped establish a new computational lab at PSGIMSR in Coimbatore, India, to expand AI, pharmacometrics and model-informed drug development training. The lab is designed to give students and researchers access to high-performance computing and hands-on research tools for drug development and healthcare analytics.

Why it matters: - The new lab is meant to strengthen India’s pipeline of talent in clinical pharmacology, pharmacometrics and AI-driven drug development. - The facility adds computing infrastructure that can support research, training and collaboration across academia and industry. - PumasAI framed the initiative as part of a broader effort to widen access to modern scientific tools and improve future drug discovery.

What happened: - PumasAI announced its role in helping establish the Dr. Ramalingam Sankaran Computational Lab for Quantitative Sciences at PSG Institute of Medical Sciences and Research, or PSGIMSR, in Coimbatore, India. - The lab was developed with SOPHAS and PSGIMSR. - The facility was officially inaugurated on July 13, 2026, by Sri L. Gopalakrishnan, Managing Trustee of PSG & Sons' Charities Trust, with leaders from PSGIMSR, SOPHAS and PumasAI present. - PumasAI, SOPHAS and PSGIMSR described the lab as a state-of-the-art center for AI, healthcare data analytics, pharmacometrics and model-informed drug development.

The details: - The lab is powered by a high-performance computing cluster. - Students, researchers and healthcare professionals will use the lab for AI-driven drug discovery, predictive health modeling, real-world evidence generation and quantitative sciences. - The facility will support research in clinical pharmacology, pharmacometrics, machine learning and healthcare analytics. - Participants will work on live research projects, industry collaborations and translational research initiatives. - The lab is designed to give hands-on experience in AI applications for drug development, clinical data modeling, pharmacometric simulations and population health analytics. - The initiative also supports SOPHAS' AI in Drug Development program by adding dedicated computational infrastructure for advanced scientific research. - The lab is named for Dr. Ramalingam Sankaran, PSGIMSR’s former dean and SOPHAS’ founding president. - The naming recognizes Dr. Sankaran’s work to advance quantitative science and computational research across India. - PumasAI said more information is available at the company’s announcement. - The release also included a LinkedIn page for PumasAI at PumasAI on LinkedIn.

Between the lines: - The project signals that drug development training is moving beyond classroom instruction toward more compute-heavy, data-driven research. - The collaboration gives PumasAI a visible role in building academic infrastructure, not just providing software. - India’s pharmaceutical sector appears to be investing further in research capacity and technical talent, which could help support longer-term innovation in healthcare and life sciences.

What’s next: - Students and researchers are expected to use the lab for ongoing research, training and collaboration. - The partners expect the facility to become a hub for AI and quantitative science work in drug development. - PumasAI said success will be measured by discoveries made in the lab, the researchers it develops and the therapies that follow.

The bottom line: - PumasAI is helping build not just tools for drug development, but the academic and computational base needed to train the next generation of researchers.